British drugmaker GlaxoSmithKline, now known as GSK and one of top-10 pharmaceutical companies in the world, has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH) to collaborate on accelerating innovative healthcare in Abu Dhabi, integrating cutting-edge treatments and personalised care.
Signed on the sidelines of Arab Health 2024, the two entities aim to further stimulate and sustain the growth of the biotechnology sector. Building on existing strengths in big data, real-world evidence, clinical trials, and clinical practices, the partnership holds the potential to revolutionise the life sciences landscape in the Emirate and around the globe.
It will leverage logistic solutions for research in areas like oncology and other prominent diseases, setting up clinical trials at key UAE sites.
Dr Asma Al Ibrahim Mannaei, Executive Director of the Research and Innovation Centre at DoH and signatory of the MoU along with Dr Averyan Vasylyev, Medical Director, GSK Gulf, commented: “The Department of Health – Abu Dhabi (DoH) remains committed to forging renowned partnerships with our local and global partners, as they enable us to further enhance healthcare outcomes and elevate the quality of life within the Emirate and beyond.
“We believe that the future of healthcare lies in genomics and the use of health data, which is why we are partnering with the biggest players in the global healthcare sector. Our collaboration with GSK Life Sciences is a perfect representation of that, as it cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation.”
Boyd Chongphaisal, Vice President and General Manager of GSK Gulf, added: “This partnership represents a significant step forward in advancing research and development programmes in the region, with the potential to make a real difference in the lives of patients not only in the UAE but also beyond. Together, GSK and the DoH are dedicated to driving innovation, enhancing health services, and improving treatment options for patients in UAE.”
On Thursday, GSK announced its results, beating market estimates for fourth-quarter results and delivering an upbeat forecast for 2024 and beyond with its pipeline of vaccines and cancer drugs.
It reported fourth-quarter sales of 8.05 billion pounds ($10.2 billion) and expects to achieve sales of more than 38 billion pounds ($48.5 billion) by 2031.
CEO Emma Walmsley said: “We are now planning for at least 12 major launches from 2025, with new vaccines and specialty medicines for infectious diseases, HIV, respiratory and oncology.”
Source:www.arabianbusiness.com
